Trials / Unknown
UnknownNCT01930864
Metformin Plus Irinotecan for Refractory Colorectal Cancer
Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- Barretos Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MetIri seeks to identify if metformin combined to irinotecan can improve tumor control.
Detailed description
MetIri is a two-stage single arm Phase II assessing the role of combination of metformin to irinotecan for colorectal cancer patients already treat with oxaliplatin, fluoropyrimidine, irinotecan and an anti-EGFr antibody if KRAS wild-type.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | metformin | metformin up to 2500mg/d |
| DRUG | irinotecan | Irinotecan 350 mg/m² IV q21d |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2013-08-29
- Last updated
- 2017-06-22
Locations
2 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01930864. Inclusion in this directory is not an endorsement.